Lilly's highly anticipated diabetes drug Mounjaro wins FDA blessing

Arriving with lofty expectations, Eli Lilly’s Mounjaro (tirzepatide) got its call-up to the big leagues on Friday, with the FDA green-lighting the type 2 diabetes and weight-loss med.

In a competitive market, which Novo Nordisk leads, can Lilly hit a home run with a drug that was shown in clinical trials to be more effective than other diabetes treatments?